Exploring Molecular Biomarkers in Cancer: A Path to Personalized Treatment

Immunotherapy and Biomarkers

Immunotherapy, compared with prior therapies has brought a new paradigm shift in cancer treatment, wherein PD-L1 expression and MSI level play an important role in the treatment response. Immune checkpoint inhibitors such as pembrolizumab, and nivolumab have proven promising results mainly in cases with tumor PD-L1 expression or MSI-H. For instance, pembrolizumab has provided long-lasting outcomes in the MSI-H CRC, ”said Dr Cha Parekh who stressed the importance of biomarker testing to identify candidates for treatment with immunotherapeutic agents.

Tumor-Agnostic Biomarkers and Treatments

A major advance in oncology is the identification and approval of therapies targeting a specific biomarker, irrespective of the primary site of the tumor. NTRK gene fusions are a type of example of this since they are present in multiple cancer subtypes. Agents such as larotrectinib and entrectinib targeting TRK have demonstrated robust therapeutic outcomes in metastatic TRK fusion cancers; such treatment strategies represent a new direction in targeted cancer therapy, which is biomarker-guided, site-agnostic therapy.

Resistance Mechanisms and Biomarker Evolution

However, this is one of the major challenges that have characterized targeted therapies – resistance. Further genetic changes, for example, in EGFR or RAS genes usually occur during the treatment process, so there is a need for second-generation inhibitors. Liquid biopsies, which involve the use of circulating tumor DNA (ctDNA), have rapidly become an invaluable approach to tracking resistance mechanisms in real time. These non-invasive tests help in the early recognition of new mutations to facilitate change in management strategies

Expanding the Horizon: Novel Biomarkers

Current research is still producing new biomarkers that have the prospect of changing the approach to dealing with cancer. For example, the molecule named PIK3CA has been discovered as a target of therapy in hormone receptor-positive breast cancer. The combination of alpelisib, a selective PI3K inhibitor, with endocrine therapy reported a marked clinical benefit among these patients. In like manner, the identification of DDR gene mutations in urothelial cancer has opened up the possibility of treating DNA damage repair pathways.

Challenges and Future Directions

Though molecular biomarkers are identified with immense potential, certain barriers prevent their adoption on a large scale. Seven major challenges have been identified: tumor heterogeneity, availability of diagnostic assays, and costs, particularly to biomarker testing. However, several of these biomarkers are not useful predictors of therapeutic outcomes, and such findings need to be tested in clinical trials.

These challenges are expected to be resolved in the future through the development of better Bioinformatics techniques, machine learning algorithms, and better integration of Multi-Omics data. In recent years, the vision of interdisciplinary approaches in biomarker research is to harvest genomic, transcriptomic, and proteomic data to identify multifaceted biomarker networks that can help design more integral therapeutic management approaches. As well, attempts to harmonize biomarker measurement and biomarker availability will be another significant way of achieving this in the future of personalized oncology.

Conclusion

The discovery and implementation of molecular biomarkers in clinical oncology have opened a new application of new concepts in cancer therapy and cancer management. Clinicians are then able to administer therapies where it is most effective and least toxic to the patient based on a tumor’s molecular signature. However, these problems exist today, but research and technological developments are certain to surmount these obstacles to ensure that each patient is treated according to their specific need. Since we keep developing new knowledge regarding cancer biology, molecular biomarkers will remain essential as we strive further towards eradicating cancer.

References

1. Kopetz, S., McDonough, S.L., Morris, V.K., Lenz, H.J., Magliocco, A.M., Atreya, C.E., Diaz, L.A., Allegra, C.J., Wang, S.E., Lieu, C.H. and Eckhardt, S.G., 2017. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
2. Phan, K. and Charif, M., 2020. Pembrolizumab for PD-L1–Positive Breast Cancer Refractory to Chemotherapy. American Journal of Therapeutics, 27(6), pp.e622-e624.
3. Lenz, H.J., Lonardi, S., Zagonel, V., Van Cutsem, E., Limon, M.L., Wong, M., Hendlisz, A., Aglietta, M., Garcia-Alfonso, P., Neyns, B. and Gelsomino, F., 2020. Nivolumab (NIVO)+ low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
4. Siena, S., Di Bartolomeo, M., Raghav, K.P.S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E. and Rodriguez, J., 2020. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
5. Drilon, A., 2019. TRK inhibitors in TRK fusion-positive cancers. Annals of Oncology, 30, pp.viii23-viii30.
6. Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H.S., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S. and Steeghs, N., 2020. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
7. Carlo, M.I., Ravichandran, V., Srinavasan, P., Bandlamudi, C., Kemel, Y., Ceyhan-Birsoy, O., Mukherjee, S., Mandelker, D., Chaim, J., Knezevic, A. and Rana, S., 2020. Cancer susceptibility mutations in patients with urothelial malignancies. Journal of Clinical Oncology, 38(5), pp.406-414.
8. Slamon, D.J., Neven, P., Chia, S., Fasching, P.A., De Laurentiis, M., Im, S.A., Petrakova, K., Bianchi, G.V., Esteva, F.J., Martín, M. and Nusch, A., 2020. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New england Journal of medicine, 382(6), pp.514-524.